Eric Lefkofsky and the Health System

Eric Lefkofsky is a graduate of the University of Michigan, an adjunct professor at the University of Chicago, and the Co-Founder and CEO of Tempus a company with the technology with an operating system to gather data to be more effective in the treatment for Cancer and other illnesses.

In fact, Eric Lefkofsky and his twenty years of experience in the advances of technology believes that the health system is lacking sufficient data and information to treat patients differently and personally, and depending on their medical history, their past diagnostics and the medications, could help doctors, researchers, and insurance companies to treat them better.

There is a lot of waste of time and money when missing a link to battle Cancer, the medical system has to depend on that critical and necessary information; clinical and molecular data have that platform to treat their patients with the facts and not only guessing from the pain.

In the mean time, Tempus has partnered with different Cancer Care Centers and Eric Lefkofsky intentions are to grow the Company and the operating system to other community hospitals, so each patient can get the health care they need and deserve, it doesn’t matter who or where you live.

The new technology of Tempus can minimize the waste and maximize the results when gathering correctly the molecular sequencing and mutations of each patient. Consequently, the patients and the doctors and everyone else will benefit with this operating system that Tempus is working to fight this battle against Cancer.

When you or someone you care and love is fighting this disease, you expect the best treatments because it is an illness that needs the best health system, a system that has to be at the top, and that is precisely what Eric Lefkofsky and Tempus wants, to be at the top to help and give real results in less time. For that reason, time is an important fact when you are fighting for your life.

Contact Eric Lefkofsky: www.crunchbase.com/person/eric-lefkofsky

Oncotarget: LncRNAs Control Cancer Metastasis through Several Signaling Pathways

Cancer is a dominant and common disease that claims the lives of many people in the world. Metastasis is a type of cancer that is characterized by malignancy. Metastasis is the combination of the early invasion and late colonization of cancer cells. Learn more about Oncotarget at Research Gate. Typically, cancer cells experience morphological transformation and change their cell-cell matrix connection to pass through the first stage of the multistep process of metastasis. The epithelial-mesenchymal transition (EMT) is a critical stage in the early events of tumor cell metastatic supply by supporting the cells with more invasive, motile potential. On the other side, Mesenchymal-epithelial transition (MET) is needed to move the cells to extravasated from the vessels into their tissue to create micrometastases. The micrometastases will eventually develop a secondary tumor after the cells survive anoikis process. Check Oncotarget journal at scimagojr.com

Long-coding RNAs (LncRNAs) are categories of transcripts that contain limited protein-coding potential and are longer than 200 nucleotides. A lot of efforts have been spent on attaining protein-coding genes to regulate cancer metastasis. Many Oncotarget articles provide limited information about the functions of LncRNAs metastasis. Several current research illustrates deregulations of LncRNAs in the different type of cancer. There is the absurd manifestation of LncRNAs in all stages of cancer development ranging from cancer initiation to progression and metastasis.

A class of EMT –inducing transcript factors such as snail, slug and ZEB1/2 are animated during EMT. Signals that grow from the tumor stroma including transforming growth factor, platelet-derived growth factor, fibroblast growth factor and insulin growth factor that is used to target EMT in cancer cells. All of these induce factors trig EMT via a complex signaling interaction involving several receptor tyrosine kinases ( RTKs) and the NOTCH, MAPK/ERK, HEDGEHOG AND PI3/Akt signaling pathways. LncRNAs have emerged as versatile control of the EMT related channels.

These findings are incredibly important to the further development of cancer treatments and protocols. By understanding growth factors in addition to other related channels, it may be possible to improve the way that cancer is addressed and understood at a molecular level. Oncotarget promotes research in these areas and spreads important findings within the global scientific community.

Visit: https://oncotarget.msubmit.net/cgi-bin/main.plex